1Klein B, et al. Interleukin-6 in human multiple myeloma. Blood,1995,85(4):863
2张之南.血液病诊断及疗效标准（第2版）[M].北京:科学出版社,1997.211-213.
3Legouffe E,et al. C-reactive protein serum level is a valuable and simple prognostic market in non Hodgkin's lymphoma. Lenk-lymphoma, 1998,31(3～4):351
6Yang J, Wezeman M, Zhang X, et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor eells from apoptosis. Cancer Cell, 2007, 12: 252-265.
7Ambrosni G, Adida C, Altieni DC. A novel anti-apoptnsis gone, survivin expressed in cancer and lymphoma. Nat Med, 1997, 3: 917-921.
8Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J, 2000, 19: 4310-4322.
9Nimmanapalli R, O Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamyein lowers Bcr-Ahl levels and induces apoptosis and differentiation of Bcr-Ahl-positive human leukemic blasts. Cancer Res, 2001,61: 1799-1804.
10Hostein I, Robertson D, Distefano F, et al. Inhibition of signal transduction by 17-allylamino- 17-demethoxygehtanamycin results in cytostasis and apnptosis. Cancer Res, 2001, 61: 4003-4009.
